27 JanInto Phase III.

Into Phase III.sa Announce Start of Phase III study of investigational Duchenne Muscular Dystrophy MedicationGlaxoSmithKline and Prosensa announced that the first patient has commenced treatment in Phase III clinical study investigating GSK2402968 , in the ambulant boys with Duchenne muscular dystrophy which has a dystrophin gene mutation amenable exon 51 exon 51 skip are . Initiation of this trial confirmed advanced plans announced already, these asset into Phase III.

The patients suffer from a progressive loss of muscle strength due to the absence or deficiency of the dystrophin protein, often making them wheelchair bound before the age of 12. Respiratory and cardiac muscle by the disease by the disease and most patients die in early adulthood due to respiratory and cardiac failure.This information was by Emperor HealthNews. From the Henry J. From the Henry J. Kaiser Family Foundation. You can change the overall Kaiser Daily Health Policy Report, search the archives and then log of email delivery of on royal health news.